
Available to mentor

I have studied opioids and opioid receptors for 30 years and have been continuously funded by NIDA since
1996. My work has been in the areas of structure-activity relationships, signaling and behavior. The long term
aim of these studies is to identify novel targets and medications to treat drug dependence and pain. My
training, both as a medicinal chemist and as a pharmacologist has been especially helpful and allowed me to
form a number of fruitful collaborations and have a general overview of the biology drug abuse. I completed a
4-year appointment as Director of the Substance Abuse Research Center and a 4 year term as President of
the International Narcotics Research Conference (INRC). I recently stepped down as Chair of the
Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics
(ASPET) and I am currently a member of the ASPET Council
Edward F. Domino Research Center Traynor Lab
-
Senior Research FellowUniversity of Leicester, Cell Physiology and Pharmacology, 1994
-
Visiting Research FellowPfizer Neuroscience Research Center, Cambridge, 1987
-
Visiting ScientistZeneca Pharmaceuticals, Alderley Park, Cheshire, 1985
-
Visiting Research FellowUniversity of Aberdeen, Unit for Research on Addictive Drugs, 1985
-
Postdoctoral FellowMax Planck Institute of Experimental Medicine, Biochemical Pharmacology, 1976
-
Pharmacy ResidentKing's Mill Hospital, Pharmacy
-
PhDUniversity of Aston, 1973
-
B.Sc. PharmacyUniversity of Aston, 1970
-
Center MemberEisenberg Family Depression Center
-
Center MemberMExperts-Opioid Research Institute
-
Li M, Gan X, Liu K, Walajapet R, Stanczyk MA, Stewart HC, Rech JC, White AD, Traynor JR. ACS Chemical Neuroscience, 2025 Jan 1; 16 (1): 16 - 29.Journal ArticleStructure-Activity Relationships and Molecular Pharmacology of Positive Allosteric Modulators of the Mu-Opioid Receptor
DOI:10.1021/acschemneuro.4c00541 PMID: 39661492 -
Burgess GE, Traynor JR, Jutkiewicz EM. 2024 Nov 21;PreprintThe effects of chronic neuropathic pain on the self-administration of highly potent MOR agonist, fentanyl.
DOI:10.1101/2024.11.19.624389 PMID: 39605379 -
Burgess GE, Traynor JR, Jutkiewicz EM. bioRxiv, 2024 Nov 21;Journal ArticleThe effects of chronic neuropathic pain states on the discriminative stimulus effect of fentanyl and other MOR agonists.
DOI:10.1101/2024.11.19.624329 PMID: PMC11601629 -
Anand JP, Moore SC, Dixon EE, Perrien Naccarato CM, West JL, Delong LJ, Burgess E, Twarozynski JJ, Traynor JR. ACS Chem Neurosci, 2024 Oct 2; 15 (19): 3587 - 3588.Journal ArticleCorrection to "Structure-Activity Relationships of the Fentanyl Scaffold: Identification of Antagonists as Potential Opioid Overdose Reversal Agents".
DOI:10.1021/acschemneuro.4c00579 PMID: 39354829 -
Demery-Poulos C, Moore SC, Levitt ES, Anand JP, Traynor JR. 2024 Aug 19;PreprintXylazine Exacerbates Fentanyl-Induced Respiratory Depression and Bradycardia.
DOI:10.1101/2024.08.16.608310 PMID: 39229079 -
Anand JP, Moore SC, Dixon EE, Perrien Naccarato CM, West JL, Delong LJ, Burgess E, Twarozynski JJ, Traynor JR. ACS Chemical Neuroscience, 2024 Aug 7; 15 (15): 2830 - 2841.Journal ArticleStructure-Activity Relationships of the Fentanyl Scaffold: Identification of Antagonists as Potential Opioid Overdose Reversal Agents
DOI:10.1021/acschemneuro.4c00203 PMID: 38994846 -
Moore S, Hamoudi R, Traynor J, Anand J. 2024 Jul 11;Proceeding / Abstract / PosterFentanyl Analogs to Replace Naloxone as Reversal Agents for Fentanyl Overdose
-
Demery-Poulos C, Kochan K, Whitaker-Fornek J, Prince T, Clements B, Levitt E, Traynor J, Anand J. 2024 Jul 10;Proceeding / Abstract / PosterIn Vitro and In Vivo Comparison of Morphine, Fentanyl, and Furanylfentanyl.

